Drug Profile
Glycyrrhizin, ammoniated
Alternative Names: Glycyron Tablets; Stronger Neo-Minophagen CLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Minophagen
- Developer Erasmus Medical Center; Minophagen; University of Texas System
- Class Antiulcers; Antivirals; Triterpenes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
- Discontinued Influenza virus infections
Most Recent Events
- 18 Dec 2007 Eisai enters into in-licensing agreement with Minophagen for Japan and other countries
- 14 Nov 2007 Data presented at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2007) added to the adverse events and Viral Infections therapeutic trials sections
- 19 Jun 2003 A preclinical study has been added to the Viral Infections antimicrobial activity section